Functional involvement of PHOSPHO1 in matrix vesicle-mediated skeletal mineralization by Roberts, Scott et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Functional involvement of PHOSPHO1 in matrix vesicle-mediated
skeletal mineralization
Citation for published version:
Roberts, S, Narisawa, S, Harmey, D, Millán, JL & Farquharson, C 2007, 'Functional involvement of
PHOSPHO1 in matrix vesicle-mediated skeletal mineralization' Journal of Bone and Mineral Research, vol
22, no. 4, pp. 617-27. DOI: 10.1359/jbmr.070108
Digital Object Identifier (DOI):
10.1359/jbmr.070108
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Journal of Bone and Mineral Research
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
 1 
Functional Involvement of PHOSPHO1 in Matrix Vesicle-Mediated 
Skeletal Mineralization 
Scott Roberts (1) , Sonoko Narisawa (2), Dympna Harmey (2), José Luis 
Millán (2) and Colin Farquharson(1)  
1Bone Biology Group, Roslin Institute, Edinburgh, Scotland, United Kingdom, 
2Oncodevelopmental Biology Program, Burnham Institute for Medical Research, La 
Jolla, CA, United States. 
 
This work was supported in part by grants AR53102, AR47908 and DE12889 from 
the National Institutes of Health, USA and the Biotechnology and Bioscience 
Research Council (BBSRC) UK. We thank Immunodiagnostic Systems Ltd, U.K. for 
a Council for Advancement and Support of Education (CASE) award (to S.J.R). 
Running Title:  Functional role of PHOSPHO1 in osteoblasts. 
 
Word total: 8102 
Abstract total: 322 
Fig total (black and white): 6  
Fig total (color): 1 
Authors emails: Scott Roberts (scott.roberts@bbsrc.ac.uk); Sonoko Narisawa 
(sonokon@burnham.org) Dympna Harmey (dharmey@scripps.edu); José Luis Millán 
(millan@burnham.org) Colin Farquharson (colin.farquharson@bbsrc.ac.uk )  
Corresponding Author: Dr Colin Farquharson 
 Roslin Institute, Roslin, Midlothian EH25 9PS, UK.  
 Tel.: 44-131-527 4399; Fax: 44-131-440-0434;  
 E-mail: Colin.Farquharson@bbsrc.ac.uk. 
 
 
 2 
 
Conflicts of Interest 
 
All authors have no conflicts of interest. 
 3 
ABSTRACT: PHOSPHO1 is a phosphatase highly expressed in bone. We 
studied its functional involvement in mineralization through the use of novel 
small molecule inhibitors. PHOSPHO1 expression was present within matrix 
vesicles and inhibition of enzyme action caused a decrease in the ability of matrix 
vesicles to calcify. 
 
Introduction: The novel phosphatase, PHOSPHO1, belongs to the haloacid 
dehalogenase superfamily of hydrolases and is capable of cleaving 
phosphoethanolamine (PEA) and phosphocholine to generate inorganic phosphate.  
Our aims in this study were to examine the expression of PHOSPHO1 in murine 
mineralizing cells and matrix vesicles (MV) and to screen a series of small-molecule 
PHOSPHO1-specific inhibitors for their ability to pharmacologically inhibit the first 
step of MV-mediated mineralization. 
Materials and Methods: q-PCR and immunohistochemistry were used to investigate 
the expression and localization profiles of PHOSPHO1. Inhibitors of PHOSPHO1’s 
PEA hydrolase activity were discovered using high throughput screening of 
commercially available chemical libraries. To asses the efficacy of these inhibitors to 
inhibit MV mineralization, MVs were isolated from TNAP deficient (Akp2 -/-) 
osteoblasts and induced to calcify in their presence.  
Results: q-PCR revealed a 120-fold higher level of PHOSPHO1 expression in bone 
compared to a range of soft tissues.  The enzyme was immunolocalized to the early 
hypertrophic chondrocytes of the growth plate and to osteoblasts of trabecular 
surfaces and infilling primary osteons of cortical bone. Isolated MVs also contained 
PHOSPHO1. PEA hydrolase activity was observed in sonicated MVs from Akp2 -/- 
osteoblasts but not intact MVs. Inhibitors to PHOSPHO1 were identified and 
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characterized. Lansoprazole and SCH202676 inhibited the mineralization of MVs 
from Akp2 -/- osteoblasts by 56.8 % and 70.7%, respectively. 
Conclusions: The results show that PHOSPHO1 localization is restricted to 
mineralizing regions of bone and growth plate and that the enzyme present within 
MVs is in an active state, inhibition of which decreases the capacity of MVs to 
mineralize. These data further support our hypothesis that PHOSPHO1 plays a role in 
the initiation of matrix mineralization. 
 
Keywords: PHOSPHO1; mineralization; osteoblasts, growth plate; alkaline 
phosphatase. 
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Introduction 
 
During the process of endochondral bone formation, chondrocytes and osteoblasts 
are believed to mineralize their extracellular matrix by promoting the initial formation 
of crystalline hydroxyapatite (HA) in the sheltered interior of membrane-limited 
matrix vesicles (MVs).(1)   This is followed by the modulation of matrix composition 
to further promote propagation of apatite outside of the MVs. (2,3)  Regulation of this 
biphasic two-step mineralization process depends on a regulated balance of a number 
of factors such as Ca2+ and inorganic phosphate (Pi) concentrations, the presence of 
matrix proteins and of adequate mineralization inhibitors including inorganic 
pyrophosphate (PPi), matrix gla protein and osteopontin.(4-8)  Three osteoblast 
molecules have been identified as affecting the controlled deposition of bone mineral 
by regulating the extracellular levels of PPi, and in turn of osteopontin, i.e., tissue-
nonspecific alkaline phosphatase (TNAP); NPP1 (a nucleotide 
pyrophosphatase/phosphodiesterase isozyme) and the ANK gene product.(9-17) 
In bone, TNAP is confined to the cell surface of osteoblasts and chondrocytes, 
including the membranes of their shed MVs.(18,19) It has been proposed that the role of 
TNAP in bone matrix is to generate Pi for HA crystallization.(20-22) However, TNAP 
has also been hypothesized to hydrolyze the mineralization inhibitor PPi (4) to 
facilitate mineral precipitation and growth.(23-25)  A variety of loss-of-function 
mutations in the human TNAP gene (ALPL) lead to hypophosphatasia, an inborn 
error-of-metabolism characterized by rickets and osteomalacia.(26) Mice with null 
mutations in the orthologous Akp2 gene phenocopy infantile hypophosphatasia(27,28) 
including elevations in the known substrates of TNAP, i.e., pyridoxal-5’-phosphate 
and PPi. Electron microscopy revealed that TNAP-deficient MVs, both in patients 
with hypophosphatasia as well as in Akp2-/- mice, contain apatite crystals, but that 
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extravesicular crystal propagation is retarded.(29,30)  This crystal growth retardation, 
referred to as the second step of MV-mediated calcification, most likely results from 
the accumulated levels of PPi in the extracellular matrix as a consequence of the lack 
of TNAP's pyrophosphatase function and the concomitant pyrophosphate-induced 
increase in osteoblast production of osteopontin, another potent inhibitor of 
calcification.(17) But, why are Akp2-/- mice born with a mineralized skeleton and still 
contain HA crystals inside their MVs? . TNAP is known to sit on the outer surface of 
the MV membrane and although it has not been adequately resolved that there is no 
TNAP inside MVs, it is likely that another enzyme is responsible for either cleaving 
PPi or elevating the intravesicular concentration of Pi so as to achieve a Pi/PPi ratio 
conducive for crystallization. 
We have previously proposed that PHOSPHO1, a novel phosphatase, plays the 
important role of increasing the Pi/PPi ratio inside MVs and thus control the first step 
of HA crystal deposition inside MVs. (31)  MVs have long been recognised to contain 
high levels of Pi.(32)  Since its identification in the chicken(33), PHOSPHO1 
orthologues have also been identified in a number of other species including humans, 
mice and zebrafish.(34,35)  However, to date no information exists on the expression of 
PHOSPHO1 in the mammalian skeleton.  PHOSPHO1, a member of the haloacid 
dehalogenase superfamily, is localised to mineralizing surfaces in both bone and 
cartilage of the chicken where its expression precedes the deposition of mineral 
suggesting that it is involved in the initial events of mineral formation.(31,36)  It is a 
soluble cytosolic enzyme that has specificity for phosphoethanolamine (PEA) and 
phosphocholine (PCho)(37,38) but not for PPi and a number of other potential 
substrates.(37)  PEA and PCho are the two most abundant phosphomonoesters in 
cartilage.(39) In addition, the proportions of membrane phospholipids containing these 
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groups decrease in MVs during mineralization, whilst 1,2-diacyl glycerol 
accumulates, indicative of phospholipase C activity.(40) This gives rise to the 
possibility of a novel mechanism whereby plasma membrane bound phosphate may 
be released through the action of PHOSPHO1 and phospholipase C to contribute to 
the Pi concentration inside the MV. 
The critical first step of mineralization mediates the deposition of the initial 
crystals of HA. We hypothesize that a TNAP-independent step involves PHOSPHO1 
functioning to increase the local concentration of Pi inside the MVs.  Thus, we would 
envisage that an inhibition of PHOSPHO1 activity would result in decreased 
mineralization within MVs.  Therefore, to test this hypothesis experimentally we have 
now examined the expression of PHOSPHO1 in murine mineralizing cells and MVs, 
screened for and characterized a series of small-molecule PHOSPHO1-specific 
inhibitors and used these compounds to pharmacologically inhibit the first step of 
MV-mediated mineralization. 
Materials and Methods 
Chemical libraries 
The LOPAC1280 (Sigma, St Louis, USA) and Spectrum (Microsource 
Discovery, Connecticut, USA) libraries were used as a source of potential small-
molecule PHOSPHO1 inhibitors. The LOPAC library consists of pharmacologically 
active compounds covering most of the major target classes i.e. G protein coupled 
receptors and kinases whereas the Spectrum library contains known bioactives, 
natural products and their derivatives. The complete libraries (3280 compounds) were 
screened. The use of these two libraries allowed the evaluation of hundreds of 
marketed drugs and biochemical standards. Each compound within these collections 
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was dissolved in 10% DMSO at approximate concentrations of 100 µM and tested at a 
final concentration of approximately 10 µM. 
Recombinant PHOSPHO1 
A cDNA corresponding to Met19-Cys267 of human PHOSPHO1 was 
amplified and cloned into the pBAD TOPO TA vector (Invitrogen) as previously 
described.(37)  Briefly, the construct was designed to express PHOSPHO1 fused to a 
V5 epitope and 6 His-tag at the C-terminus.  A clone containing the PHOSPHO1 
fragment in the correct orientation was identified by restriction digestion of plasmid 
minipreparations.  E. coli were grown in Lauria-Bertani broth (10 litres, 370C) and 
recombinant protein expression was induced by treatment with 0.1% (w/v) L-
arabonose for 4 h. 
Inhibitor Screening 
 The semi-automated screening utilized a Beckman Coulter dual bridge 
Biomek FX liquid handler, consisting of a 96 tip head bridge for full plate pipetting. 
The reactions were measured in 96-well plates containing 25 µl 20 mM MES-NaOH, 
pH 6.7, 0.01% (w/v) BSA, 0.0125% (v/v) Tween 20, 2mM MgCl2, 62.5 µM PEA, 10 
µM test compound and 500 ng (15.5 pmoles) of purified recombinant PHOSPHO1. 
Substrate addition was used to initiate the reaction thus allowing for an 
enzyme/compound pre-incubation. Reactions were allowed to proceed for 60 min at 
room temperature then stopped by the addition of 50 µl BIOMOL green reagent 
(Biomol International, L. P., Plymouth Meeting, PA). The absorbance of each well 
was measured at 620 nm and the inhibitory effect of each compound calculated as a 
percentage in relation to controls containing 1% (v/v) DMSO, since each compound 
was dissolved in 10% DMSO giving 1% in the final reaction. Each compound that 
exhibited an inhibition of 40% or more using the automated system was reconfirmed 
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manually, in duplicate, to eliminate the possibility of false positives. The assay used 
included negative controls (i.e. no inhibition, contained both enzyme and PEA) and 
positive control (i.e. 100% inhibition, contained only PEA) 
Characterisation of Inhibitors 
The IC50 for each inhibitor was determined using the phosphatase assay 
detailed above. The inhibitor concentration was varied between 100 and 0.3 µM with 
each individual reaction repeated in triplicate. The data of absorbance vs. inhibitor 
concentration was plotted using SigmaPlot and four parameter logistic curve fitted. 
The IC50 was calculated using the equation; y = min + (max-min/1+ 10(logEC50-
x)Hillslope). Effect of inhibitors on recombinant mammalian expressed TNAP protein(41) 
was assessed under optimal conditions; 1M diethanolamine buffer pH 9.6, 1mM 
MgCl2, 20 µM ZnCl2, 20 µM inhibitor, 0.5mM p-nitrophenolphosphate (pNPP). This 
assay was repeated using recombinant PHOSPHO1 under the optimal conditions 
described below. Absorbance’s were measured at 405 nm. 
The continuous phosphatase assay to determine kinetic parameters of the 
reactions involved monitoring the dephosphorylation of pNPP which causes an 
absorbance change at 405 nm. The reactions were measured in 96-well plates 
containing 20 mM MES-NaOH, pH 6.7, 0.01% (w/v) BSA, 0.0125% (v/v) Tween 20, 
2mM MgCl2, and 1.5 µM purified recombinant PHOSPHO1 at room temperature. 
pNPP and inhibitor concentrations were varied accordingly. Absorbance’s were 
measured continuously at 405 nm using a VICTOR HTS plate-reader.(37)   
Immunolocalization of PHOSPHO1 within long bones 
 Ten-day old male mice were euthenized by cervical dislocation and tibiae 
were fixed in 4% paraformaldeyde in PBS for 24 h before decalcification in 0.5M 
EDTA (pH 8.0) for a further 24 h at 40C. The fixed tissue was dehydrated and paraffin 
 10 
embedded using standard techniques. Paraffin sections (6 µm) were dewaxed in 
xylene and rehydrated through a graded series of alcohol solutions and antigen 
retrieval was achieved by heating in sodium citrate for 90 minutes at 70 °C followed 
by extensive washing in PBS. Endogenous peroxidases were blocked by incubating 
the sections with 3% hydrogen peroxide (in methanol), followed by 3 washes in PBS. 
Unspecific protein binding was blocked by normal goat serum (1:5) diluted in PBS 
for 30 min.  Rabbit antisera to mouse PHOSPHO1 (a generous gift from Professor 
Ikramuddin Aukhil, University of Florida, USA) was diluted 1:200 in PBS and 
incubated with the tissue section at 4°C overnight. Control sections received a similar 
dilution of normal rabbit serum.  Following this the sections were washed in PBS, and 
incubated with a 1:100 dilution of goat anti rabbit IgG - peroxidase (DAKO, 
Cambridgeshire, UK) for 60 min.  DAB substrate reagent (0.06% DAB, 0.1% H2O2 in 
PBS) was incubated for 8 min, rinsed in PBS and counterstained with Mayer’s 
hematoxylin (Sigma) for 5 min. The sections were finally dehydrated and mounted in 
DePeX.   
Isolation of MVs from Chick Growth Plate Cartilage  
All animal studies and protocols were approved by the Institutional Animal 
Users Committees of both Roslin Institute and Burnham Institute for Medical 
Research.  Under sterile conditions, growth plate cartilage from 3-week-old male 
broiler chickens was collected and diced. MVs were released by incubating the tissue 
at 37 °C with 0.45% collagenase (Worthington, type II) in 50mM Tris-HCl pH 7.6, 
120 mM NaCl and 10 mM KCl for 3 h with constant agitation. The digested tissue 
was passed through a 40 µM sieve to remove undigested material. MVs were 
harvested from the digest by differential centrifugation as previously described.(42) 
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Briefly, the digest was centrifuged for 30 min at 1500 g to collect chondrocytes, then 
at 30, 000 g to remove sub – cellular debris and finally at 250, 000g to pellet MVs.  
Isolation of MVs from primary cultured calvarial osteoblasts  
Mouse calvarial cells were isolated from 3-day-old mice through sequential 
collagenase digestion, as previously described.(11,16) Calvarial cells from Akp2-/-, 
Akp2+/- and wild-type mice were pooled separately and plated at a density of  
20,000/cm2 in alpha-MEM (Gibco, Paisley, UK) containing 10% FBS, 50 µg/ml 
ascorbate for a period of 21 days. The cell monolayer was washed with 50mM Tris-
HCl pH 7.6, 120 mM NaCl and 10 mM KCl, and then incubated with 0.45% 
collagenase (Worthington, type II) in 50 mM Tris-HCl pH 7.6, 120 mM NaCl and 10 
mM KCl at 37ºC for 120 min at 37ºC, with constant agitation. This cell suspension 
was subjected to differential centrifugation as described above to isolate both cells 
and MVs.   
MV phosphatase activity and mineralization ability 
Phosphatase activity within chick and mouse MVs was determined using the 
standard discontinuous colorimetric assay. (43)  In brief, reactions were measured in 
96-well plates containing 200 µl of 25% (w/v) glycerol, 20 mM TBS, pH 7.2, 25 
µg/ml BSA, 2.5 mM PEA, 2 mM MgCl2 and 12 µg MV protein.(37)  PHOSPHO1 
inhibitors at a final concentration of 1mM were used where appropriate. The mouse 
MVs were either left intact or ruptured by sonication to release the cytosolic contents.  
TNAP activity was determined using the Thermo-line ALP reagent (Melbourne, 
Australia). Total TNAP activity was expressed as nmoles pNPP hydrolysed/ min/mg 
protein.  The in-vitro calcification ability of MV was determined by their ability to 
form calcium phosphate in vitro.(44)  In brief, samples of MV protein (15µg of chick 
MVs and 20µg of TNAP null osteoblast derived MVs) were incubated in calcification 
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buffer in the presence of 0 to 3 mM phosphoester substrate for 5.5 h at 37°C. The 
reaction was terminated by centrifugation at 8800g for 30 minutes to pellet both MVs 
and any calcium phosphate mineral formed during incubation. The pellet was then 
solubilised with 0.6N HCl for 24 h and used directly in for calcium quantification 
using the O-cresolpthalein complexone method (CPC Kit, Thermotrace). 
Western Blotting of PHOSPHO1 within MVs 
  Murine MVs were analysed for the presence of PHOSPHO1 by 
immunoblotting. MV preparations were lysed in PBS containing 1.6 mg/ml of 
Complete® protease inhibitor cocktail (Roche, Lewes, UK). Samples corresponding to 
10 µg total protein were incubated at 70˚C for 10 minutes in LDS sample buffer 
before loading. Samples were ran on a 10% Bis-Tris NuPAGE gel and electroblotted 
to nitrocellulose, which were incubated in blocking solution (5% non-fat milk in Tris 
buffered saline with 0.1% Tween 20).  The membranes were then probed with a 1:750 
dilution of rabbit-anti-PHOSPHO1 antisera in blocking solution and washed three 
times with PBS. Blots were then incubated with goat anti rabbit IgG-peroxidase 
(DAKO) diluted 1:2,000 in blocking solution. The immune complexes were then 
visualized by enhanced chemiluminescence 
Real Time (Quantitative) Polymerase Chain reaction (qPCR) of PHOSPHO1 within 
murine tissues 
 Tissues from several 10 day-old male mice were pooled and RNA was isolated 
by phenol/chloroform extraction and used directly in a quantitative RT-PCR reaction.  
The Brilliant® SYBR® Green QRT-PCR Master Mix Kit (Stratagene) method was 
utilised to allow quantification by fluorescence during the PCR reaction. Briefly 25µl 
SYBR green mastermix was added to 10ng RNA along with 0.2µM forward and 
reverse primers (forward: GACAATGAGCGGGTGTTTTC reverse: 
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GGGGATGGTCTCGTAGACAG). The RT-PCR reaction was cycled in a Perkin-
Elmer Applied Biosystems Prism 7700 sequence detector as follows: 50°C for 30 
minutes (RT step), 95°C for 10 minutes, 40 cycles of 95°C for 30 seconds 57°C for 30 
seconds and 72°C for 1 minute. Each tissue sample tested was tested in triplicate and 
compared to 18S RNA (classic II primers, Ambion) external control which allowed 
normalisation of results. A dilution series of both gene of interest and external control 
were carried out and subjected to an identical PCR to allow estimation of PCR 
efficiency.  Relative differences in expression were calculated using the 2-rCT method. 
Semi Quantitative PCR of osteoblast specific genes 
 
Murine osteoblasts (Akp2-/- and wild-type) were cultured in alpha-MEM 
containing 10% FBS, 50 µg/ml ascorbate and ß-glycerophosphate (10mmol/L) for up 
to 14-days. Total RNAs were extracted by phenol/chloroform extraction and treated 
with DNase I (Ambion) according to the manufacturer's instructions. The RT-PCR 
reaction was carried out using the SUPERSCRIPT - First Strand synthesis system for 
RT-PCR with Oligo dT (Roche). Primer pairs for β-Actin RNA were used as a 
control. The reaction mixture contained 5µg RNA, 500ng Oligo dT, 2µl 10 x RT 
buffer, 2mM MgCl2 , 10mM DTT, 0.5mM DNTP’s, 200ul Superscript enzyme. The 
reaction was then cycled as follows; 25◦C for 10 min, 42◦C for 50 min and 70◦C for 
15 min. The cDNA was used directly in a PCR reaction containing; 0.2mM dNTP mix 
(Promega), 5µl 10x PCR Buffer (Roche), 5 units Taq polymerase (Roche), 0.5µM of 
the forward and reverse primers and 1µl cDNA. This was then cycled in at: 94°C for 5 
minutes, thirty cycles of 94°C for 30 seconds 57°C for 30 seconds and 72°C for 1 
minute and finally one step on 72°C for 10 minutes. The primers sets were designed 
to span at least one intron so that any amplification from contaminating genomic 
DNA would be identified. The primers were PHOSPHO1 (forward: 
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GACAATGAGCGGGTGTTTTC reverse: GGGGATGGTCTCGTAGACAG) TNAP 
(forward: ACTACCACTCGGGTGAACCA reverse: 
TGAGATCCAGGCCATCTAGC) ß-actin (forward: 
TCCATCATGAAGTGTGACGT reverse: ACGATGGAGGGGCCGGACTC) Each 
reaction was analyzed on 1.5% agarose gels run in the presence of ethidium bromide 
(250 µg/l). 
Statistical analysis 
 Analysis of variance (ANOVA) was performed to determine the significance 
of a given result. General Linear Model analysis incorporating pair-wise comparisons 
using Tukeys test was used to compare groups within the ANOVA models.  All data 
are expressed as the mean +/- SD. Statistical analysis was performed using Minitab 
14. Statistical significance was accepted at P<0.05.  
Results 
PHOSPHO1 Expression in Whole Tissues 
To investigate the levels of PHOSPHO1 gene expression in different 
mammalian tissues, we used qPCR to obtain relative expression values. Bone had the 
highest expression levels while the least amount of PHOSPHO1 transcript was found 
in the liver (Fig. 1).  The difference in expression between these two tissue types was 
~120 fold. Furthermore, low transcript levels were detectable in all tissues examined; 
heart (5.67), bone marrow (3.57), adipose tissue (3.38), brain (1.96) and gut (1.20) 
(numbers in brackets represent the fold difference when compared to PHOSPHO1 
expression in liver, which was arbitrarily set as 1 for comparison).  
Immunolocalization of PHOSPHO1 to skeletal cells and Identification of 
PHOSPHO1 in MVs 
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The high expression level of PHOSPHO1 in bone observed by qPCR was 
confirmed and extended by the immunolocalization of PHOSPHO1 to primary 
regions of ossification in both growth plate cartilage and trabecular and cortical bone.  
PHOSPHO1 was restricted to the hypertrophic zone of the growth plate (Fig 2a).  No 
staining was observed in the proliferating chondrocytes and in comparison to the pre-
hypertrophic chondrocytes the terminally differentiated cells displayed little staining. 
PHOSPHO1 immunoreactivity was also observed within the chondrocytes of the 
developing secondary ossification centre (Fig 2b).  PHOSPHO1 was also present on 
the surface of the trabecular bone of the metaphysis as well as within the osteoblasts 
lining the bone forming surfaces of the primary osteons within the periosteal region of 
cortical bone (Figs. 2c and d). All control sections were negative. Confirmation that 
PHOSPHO1 is a strong candidate as a modulator of matrix mineralization was 
obtained by the detection of PHOSPHO1 in MVs isolated from mouse calvarial 
osteoblasts (Fig. 2e). A single band of 29 KDa was detected, which agrees with the 
expected protein size for one of the PHOSPHO1 splice variants (Roberts et al. 
unpublished observation). 
Identification of Active PHOSPHO1 in MVs 
  To determine if PHOSPHO1 present in murine MVs was active, we tested for 
hydrolase activity within intact and sonicated MVs isolated from cultures of Akp2-/-, 
Akp2+/- and wild-type osteoblasts.  This strategy was adopted to eliminate the 
possibility that TNAP hydrolysis of PEA may mask PHOSPHO1 activity. Cell 
phenotype was confirmed using ALP histochemistry and mineralization capability by 
von Kossa staining (data not shown). TNAP activity of intact MVs purified from 
these cultures mirrored that of TNAP histochemistry (Fig.3a).  MV preparations were 
used directly in the standard discontinuous colorimetric assay.  It was found that the 
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wild-type and Akp2-/-  intact MVs had a hydrolase activity of 3.3 + 0.4 and 0.07 + 0.4 
nmol.min-1mg-1 MV protein, respectively. TNAP heterozygous MVs had an activity 
of 1.68 + 0.5 nmol.min-1mg-1 MV protein (Fig. 3b).  Sonication of the MV 
preparation, to assess PHOSPHO1 and TNAP combined activity, caused an increase 
of approximately 1 nmol.min-1mg- in all cases (P<0.05), indicting that the enzyme 
responsible for this increased hydrolysis is cytosolic. 
Is PHOSPHO1 Expression influenced by the presence of TNAP? 
To analyse whether PHOSPHO1 expression was altered by TNAP expression, 
RNA was extracted from cells cultured for up to 14 days under mineralizing 
conditions.  The TNAP genotype was confirmed by PCR and PHOSPHO1 expression 
was not altered by the background TNAP status of the cells nor by continuous culture 
for up to 14-days (Fig. 4).  
Identification and Characterization of PHOSPHO1 Inhibitors 
In order to be able to conduct studies to examine the effects of PHOSPHO1 
inhibition on MV-mediated calcification, we first needed to identify and characterize 
small molecule inhibitors specific for PHOSPHO1. Consequently we screened two 
well known chemical libraries, i.e., the LOPAC and the Spectrum libraries and 
identified seventeen compounds capable of inhibiting recombinant PHOSPHO1 
activity with IC50 values of 10 µM or less. From these seventeen compounds, three 
were selected based on certain criteria, i.e. solubility,  reconfirmed inhibitory potential 
of 80% or more and also the absence of any reactive groups such as thiols etc. This 
led to the identification of SCH 202676; Lansoprazole and Ebselen as compounds for 
further investigation (structures shown in Fig.  5a).  
The calculated IC50 values for each of these compounds when tested against 
PHOSPHO1-mediated hydrolysis of PEA were 1.97 ± 0.01 µM (SCH 202676), 4.71 ± 
 17 
0.1 µM (Lansoprazole) and 2.81 ± 0.04 µM (Ebseleln) (Fig. 5b).. The PHOSPHO1 
inhibition displayed by each of these compounds was also investigated by analysing 
data of initial reaction velocity in the presence of varying concentrations of inhibitor 
and pNPP. From analysis of the resultant Line-Weaver Burke plots all four inhibitors 
displayed lines which intercept after the y axis, close to the x axis which is a hallmark 
of non-competitive inhibition (data not shown). A Michaeles-Menten curve was 
constructed under saturating quantities of pNPP which also indicated that the 
inhibitors are of a non-competitive nature (data not shown) The inhibitor constant Ki, 
for the inhibitor/enzyme complex, was also calculated for each of these reactions with 
SCH 202676, Lansoprazole and Ebseleln displaying Ki values of 1.08 ± 0.83 , 71.28 ± 
9.21and 31.00 ± 0.74 µM, respectively.  
Effect of PHOSPHO1 Inhibitors on MV Phosphatase Activity 
With these novel inhibitors at hand, we used chick MV protein directly as a 
source of wild-type PHOSPHO1 in a discontinuous colorimetric assay to assess the 
effect of inhibiting PHOSPHO1 activity on Pi generation. Each inhibitor was used at a 
concentration of 1 mM.   The uninhibited MV protein exhibits a PEA hydrolase 
activity of  87.1 ± 1.8 nmol min-1 mg-1 whereas in the presence of Lansoprazole and  
SCH202676 this activity was reduced to 62.9  ± 1.1 nmol min-1 mg-1 and 73.0  ± 2.7 
nmol min-1 mg-1 respectively (Fig. 6a). In comparison to the uninhibited reactions 
these activities relate to a reduction in activity of approximately 28% for 
Lansoprazole (P<0.001) and 16% for SCH202676 (P<0.001). Neither Lansoprazole 
nor SCH202676 interfered with the ability of TNAP to catalyse the hydrolysis of 
pNPP under optimal conditions, but did exhibit inhibition of PHOSPHO1 mediated 
hydrolysis of pNPP similar to that seen when using PEA as a substrate (Fig. 6b). 
Effect of PHOSPHO1 Inhibitors on MV Calcification 
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Using the in vitro calcification assay we found that PEA supports the calcification of 
chick MVs, purified from growth plate cartilage, comparable to that shown by the 
phosphoester ß-glycerophosphate, 1.0 ± 0.01 and 1.3 ± 0.04 units of precipitated 
calcium (Fig. 7a).  Chick MVs preparations were subsequently incubated with 1mM 
of Lansoprazole or SCH202676 which resulted in a slight decrease in calcifying 
potential in the presence of PEA (approximately 10% with each inhibitor (P<0.001), 
(Fig. 7b).  
To increase the sensitivity of this assay the inhibitor actions were examined on 
MVs extracted from cultured Akp2-/- osteoblasts. This strategy eliminated the 
possibility of TNAP hydrolysing the phosphoester and potentially masking the effects 
of the PHOSPHO1 inhibitors.   Using this strategy, a much more pronounced 
inhibitory effect was seen with Lansoprazole and SCH202676. In comparison to 
uninhibited reactions, Lansoprazole exhibited a 56.8 % inhibition of calcification 
(P<0.01) whereas SCH202676 inhibited calcification by 70.7% (P<0.001) (Fig  7c). 
Discussion 
The mechanisms and proteins regulating matrix mineralization are not yet fully 
understood, and we are still unclear if under physiological conditions mineralization 
is due to the presence of promoters of mineralization (active process) or a lack of 
mineralization inhibitors (passive process).(45)  Notwithstanding the presence of an 
optimum balance of both inhibitors and promoters, the mineralization process is 
clearly dependent on the attainment of sufficiently high concentrations of Pi for the 
formation of de novo calcium phosphate crystals.  Generation of Pi for mineralization 
has long been attributed to the actions of TNAP(6,20) but it is now clear that the 
production of Pi for matrix calcification is not entirely attributable to TNAP activity. 
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In newborn Akp2 knockout mice, bone development and mineralization appear 
normal even though hypomineralization and other abnormalities do subsequently 
appear.(11,27,28) Although mechanisms involving in utero protection cannot be ruled 
out the postnatal mineralization defects in Akp2-/- mice are likely to be due to a build 
up of PPi, a known substrate of TNAP(21) and a potent inhibitor of HA crystal 
formation.(4) Indeed, hypomineralization is greatly reduced in [Akp2-/-; Enpp1-/-] 
double-knockout mice where extracellular PPi (ePPi) concentrations return to normal 
after ablating NPP1 enzyme activity, i.e., the enzyme that produces PPi at the surface 
of osteoblasts and MVs.(10,11) Hypomineralization in these double knockout mice is 
corrected in a site-specific manner in the calvaria and vertebrae while residual 
hypomineralization remains in metatarsals and long bones.(6)  Mechanistically, the 
aforementioned build-up of ePPi in Akp2-/- mice in turn leads to upregulated 
osteopontin expression by Akp2-/- osteoblasts(17) and it has recently been shown that 
it is the combined accumulation of ePPi and OPN that causes osteomalacia in Akp2-/- 
mice.(17)  
The location of TNAP to the outer surface of MV membrane and the 
demonstrated role of this enzyme as a pyrophosphatase in vivo suggests that other 
molecules or mechanisms are responsible for increasing intravesicular Pi levels so as 
to achieve a Pi/PPi ratio conducive for crystallization.  The sodium-dependent 
phosphate type III transporter Pit-1 (GLvr-1)(46-48) and other phosphatases such as, 
pyrophosphatase, AMPase and ATPase, known to be present in MVs(6,49,50) may be 
involved.  In this present study we now provide the first functional evidence that 
PHOSPHO1 is a MV phosphatase involved in skeletal mineralization. 
The immunolocalization of PHOSPHO1 in the mouse is consistent with its 
presumed role in matrix mineralization.  PHOSPHO1 was localized in chondrocytes 
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in the early hypertrophic zone of the growth plate and to bone forming surfaces in 
both long bones (trabecular and cortical) and the site of the developing secondary 
ossification centre.  This distribution, together with the absence of strong 
PHOSPHO1 immunoreactivity in the hypertrophic chondrocytes situated deep in the 
mineralized zone, suggests that PHOSPHO1 has a pivotal role in the initial stages of 
the mineralization process and is required for the de novo formation of the inorganic 
phase but not for the continued crystal growth of hydroxyapatite.   This concurs with 
studies of the developing chick skeleton, where the expression of PHOSPHO1 in the 
mid-shaft of long bones preceded alizarin red staining, indicative of calcium 
deposition.(31)  This localisation of PHOSPHO1 to bone forming surfaces mirrors that 
of TNAP (51,52), and perhaps indicates synergy between the two enzymes to achieve 
HA crystal growth.   Although likely working in concert, no evidence was obtained to 
suggest that PHOSPHO1 expression was influenced by the presence/absence of 
TNAP possibly indicating that PHOSPHO1 is functioning independently from TNAP. 
The matrix staining of PHOSPHO1 on bone forming surfaces is likely to reflect 
the presence of the enzyme in osteoblast derived MVs, which are deposited within 
newly formed osteoid. (53)  Indeed the presence of PHOSPHO1 in MVs derived from 
calvarial osteoblasts was confirmed by immunoblotting as was the ability of TNAP 
null MV lysates to catalyse the hydrolysis of PEA. This indicates that the enzyme 
responsible for this degradation is cytosolic and, as according to the KEGG 
database(54) only TNAP and PHOSPHO1 have the ability to cleave PEA, it is likely 
that this cytosolic enzyme is in fact PHOSPHO1. 
The high expression of PHOSPHO1 in bone noted by qPCR is consistent with the 
immunolocalization of PHOSPHO1, however, its low basal expression in a number of 
soft tissues may indicate other putative roles for this enzyme. Phosphocholine is an 
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important regulatory compound for the metabolism of phosphatidylcholine, the major 
phospholipid in mammalian tissues.(55)  In heart muscle it has been documented that 
the PCho pool is much lower than that in the liver or HeLa Cells (56), however the 
enzyme responsible for this hydrolysis remains unknown.(57)  It is interesting to 
speculate that this step may be controlled by the PCho activity of PHOSPHO1(37,38) 
thereby explaining the low expression in the heart and implicating PHOSPHO1 in a 
possible novel pathway which may be mediated by one of the alternate transcript 
from the PHOSPHO1 gene. 
From the high throughput screening of compounds from the two chemical 
libraries LOPAC and SPECTRUM, 17 inhibitors of PHOSPHO1 mediated hydrolysis 
of PEA were observed. Many of these inhibitors, however, had undesirable 
properties, such as cisplatin that conceivably intercalates between the disulphide 
bridge in PHOSPHO1.  In addition, compounds such as the dimeric disulphide 
containing compound thiram would be susceptible to nucleophlic attack and 
reduction.  Other compounds deemed unsuitable included those which possess thiol 
groups.  The functional group of the amino acid cysteine is indeed a thiol, therefore it 
is likely that compounds such as mercaptobenzothiazole, which was identified during 
this screen, would cause an inhibition through chemical modification of the 
PHOSPHO1 structure.  This compound structure screening led to the identification of 
the three inhibitors; SCH 202676, Lansoprazole and Ebseleln deemed suitable for 
further characterization. 
  Lansoprazole and SCH 202676 decreased the amount of liberated Pi using 
isolated chick MV by 28% and 16% respectively. Ebselen has no effect on PEA 
hydrolase activity of MVs thus it is likely that this inhibitor is not effective against the 
wild-type enzyme. As this is a non-competitive inhibitor and binds at a site distinct 
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from the active site, it is conceivable that Ebselen is binding recombinant 
PHOSPHO1 at the C terminal tagged region thus inhibiting the recombinant but not 
the wild-type enzyme.  SCH 202676 is a thiadiazole compound that acts upon and 
inhibits signalling through G protein-coupled receptors.(58) It is thought that this 
compound is an allosteric modulator of G protein-coupled receptors and may 
recognise an intracellular regulatory domain of the protein, however it’s exact mode 
of inhibition remains unknown.(59)  In contrast, Lansoprazole is an extremely well-
characterised compound.  This drug belongs to a class of compounds known as the 2-
(2-pyridylmethylsulfinyl)-1H-benzimidazoles and is an inhibitor of H+ and K+ 
(H+/K+)-ATPase of stomach parietal cells.  Under acidic conditions, Lansoprazole is 
converted into an acid activated cationic sulphenamide form (AG2000) which acts as 
a proton pump inhibitor(60), blocking the final step of acid production. 
The effect of Lansoprazole and SCH 202676 on Pi release by chick MVs was 
greater than their inhibitory effect on MV calcification which was only ~10% with 
each inhibitor. This imbalance is possibly due to TNAP activity of the MVs 
preparations masking the effects of the PHOSPHO1 inhibitors by promoting PPi 
hydrolysis and/or maintaining Pi levels at about the minimum threshold for 
mineralization to occur normally. Alternatively, preformed mineral crystals found 
within MVs may be acting as local nucleators allowing mineral propagation, even in 
the presence of PHOSPHO1 inhibitors. To avoid interference from TNAP in the assay 
system, we used MVs isolated from calvaria of TNAP null mice.  In this case a more 
profound inhibition was observed; SCH 202676 and Lansoprazole caused a 71 and 
57% decrease in calcification, respectively.  This indicates that PHOSPHO1 which is 
sequestered within the lumen of the MV has the ability to hydrolyse PEA to increase 
the intravesicular concentrations of Pi to allow mineralization to occur.  This is likely 
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to occur in synergy with phosphate(46-48) and calcium(61-63) transporters to facilitate the 
production of the initial crystals for hydroxyapatite deposition. SCH202676 is an 
allosteric antagonist of dopamine receptors and Lansoprazole is a proton pump 
inhibitor, and both are already being used in the treatment of patients, however to the 
best of our knowledge their use has not been reported to be associated with rickets or 
osteomalacia.  
In conclusion the Phospho1 gene is highly expressed in bone tissue and the 
PHOSPHO1 protein localization is restricted to sites of skeletal mineralization in the 
mouse. Further, PHOSPHO1 protein is cytosolic and active within murine osteoblast-
derived MVs retaining the ability to hydrolyse the PEA, as previously demonstrated 
with the recombinant enzyme.(37,38) In addition, the PHOSPHO1 inhibitors SCH 
202676 and Lansoprazole have the ability to modulate the in vitro mineralization of 
MVs. These data further strengthens the hypothesis that PHOSPHO1 has a role in 
bone mineralization, likely to be linked to the glycerolipid metabolism pathways 
involving the degradation of phosphatidylethanolamine and phosphatidylcholine and 
the production of Pi for MV mediated mineralization. 
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Figure Legends 
Fig. 1. qPCR of PHOSPHO1 in murine tissues. Data shows relative expression of 
PHOSPHO1 with reference to that of the liver which is set at 1 due to the lowest 
expression level of this tissue. RNA was isolated from mouse tissues by phenol 
chloroform extraction and used directly in the qPCR reaction utilising the DNA 
intercalating dye, SYBR green. Results are mean ± SD (n = 3). 
Fig. 2. Expression of PHOSPHO1 in mouse tibial sections and MV. (A). Strong 
specific localization within the growth plate was limited to the early hypertrophic 
chondrocytes (arrows). Chondrocytes of the proliferating zone were negative (*). 
Trabecular bone surfaces within the metaphyseal region of the tibia were also positive 
(arrow-heads) (Scale Bar = 100µm) (B). Positive PHOSPHO1 staining in the 
developing secondary ossification center of the tibia (arrows) (Scale bar = 100µm) 
(C). Higher magnification of positively stained osteoblasts lining the bone forming 
surfaces of primary osteons in cortical bone (arrows) (Bar = 50µm). (D). Trabecular 
bone surfaces within the metaphysis containing positively stained osteoblasts (arrows) 
(Scale Bar = 50µm). Control sections are displayed in the lower panel of each pair (B-
D).  (E). Immunoblot showing the localisation of PHOSPHO1 to murine MVs 
isolated from calvarial osteoblasts. Immunoreactivity is compared to that of 
recombinant PHOSPHO1. The recombinant protein is of greater mass due to the 
presence of a C-terminal tagged region. 
Fig. 3.  Hydrolase activity of MVs from Wt, Akp2+/- and Akp2-/- osteoblasts. (A) 
pNPP and (B) PEA phosphatase activity of MV preparations. Data is presented as the 
mean + SD of nine replicates from each genotype. PEA hydrolase activity was 
significantly higher (p<0.05) in sonicated vs. intact MVs. 
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Fig. 4. Analysis of TNAP and PHOSPHO1 expression in Wt and Akp2-/- 
osteoblasts Comparison of TNAP and PHOSPHO1 expression between Wt and Akp2-
/- osteoblasts over a 14 day culture period.  
Fig. 5. Identification of PHOSPHO1 inhibitors. (A). Structures of three compounds 
found to inhibit recombinant PHOSPHO1 by over 80%. (B). IC50 determination of 
each PHOSPHO1 inhibitor. Recombinant human PHOSPHO1 was incubated with 
various concentrations of SCH 202676, Lansoprazole or Ebseleln at room temperature 
for 60 min and phosphate released during the reaction was measured. Results are 
mean ± SD (n = 3). 
Fig. 6. PEA hydrolase potential of chick MVs in the presence of PHOSPHO1 
inhibitors. (A) Chick MVs were isolated from tibial growth plate cartilage and used 
directly to measure phosphate released, as an indicator of PEA hydrolase activity, in 
the presence of  Ebselen (EBS), Lansoprazole (LAN) or SCH 202676 (SCH). (B) 
Effect of inhibitors on PHOSPHO1 (open bars) and TNAP (shaded bars) pNPP 
hydrolase activity under optimal conditions. Results are mean ± SD (n = 3, *** = 
p<0.001 when inhibited reaction compared to uninhibited reaction).  
Fig. 7. Potential for MVs to calcify in vitro in the presence of PEA and 
PHOSPHO1 Inhibitors. (A). The ability of chick MVs to induce calcification in the 
presence of 3mM PEA and 3mM ß-glycerophosphate (RU, relative units). (B). 
Calcification of chick MVs in the presence of 1mM Lansoprazole (LAN) or SCH 
202676 (SCH) (C). Calcification of murine TNAP null MVs in the presence of 1mM 
Lansoprazole (LAN) or SCH 202676 (SCH). Results are mean ± SD (n = 3, *** = 
p<0.001, ** = p<0.01 when inhibited reaction compared to uninhibited reactions). 
 
